search
Back to results

Evaluation of The MetaNeb® System to Reduce Postoperative Pulmonary Complications

Primary Purpose

Atelectasis, Pulmonary Complications

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
MetaNeb® System
Sponsored by
Hill-Rom
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Atelectasis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Age ≥ 18 years Post-thoracic, -upper abdominal or -aortic surgery Open surgical procedure Incision at or above the umbilicus

High risk defined by:

Documented ASA class ≥ 3 OR

Documented ASA class 2 AND One or more of the following:

Current smoker or smoking history within past 6 months History of COPD Documented obesity and/or BMI ≥ 30 kg/m2 Age ≥ 75

Exclusion Criteria:

Contraindication to Continuous High Frequency Oscillation (CHFO) therapy Minimally invasive, or ". . . scopic" procedure. Spinal surgery involving a posterior approach Surgery for organ transplant Chronic invasive positive pressure ventilation (PPV)

Sites / Locations

  • Lahey Hospital and Medical Center
  • Carolinas Medical Center
  • Hospital of the University of Pennsylvania

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

METANEB

Arm Description

Patients will receive standard care with the addition of therapy with The MetaNeb® System.

Outcomes

Primary Outcome Measures

Significant Postoperative Pulmonary Complication Incidence
Patient Requires Prolonged Mechanical Ventilation, Patient requires prolonged respiratory support for > 24 hours post-surgery, Diagnosis of Pneumonia Within Seven (7) Days, Readmission to ICU (or transfer to an elevated level of care) for pulmonary complications within seven (7) days of discharge

Secondary Outcome Measures

Requirement for invasive mechanical ventilation for > 48 hours within seven (7) days of the post-surgical hospital admission
Requirement for respiratory support > 48 hours within seven (7) days of the post-surgical hospital admission
Length of ICU stay during initial hospital stay
Length of hospital stay during initial hospital stay
Readmission to ICU and transfers to elevated level of care for pulmonary complications during initial hospital stay
Readmission to hospital
Time on Mechanical Ventilation

Full Information

First Posted
December 2, 2015
Last Updated
September 11, 2017
Sponsor
Hill-Rom
search

1. Study Identification

Unique Protocol Identification Number
NCT02627742
Brief Title
Evaluation of The MetaNeb® System to Reduce Postoperative Pulmonary Complications
Official Title
Evaluation of a Practice Change to Include The MetaNeb® System to Reduce Postoperative Pulmonary Complications
Study Type
Interventional

2. Study Status

Record Verification Date
September 2017
Overall Recruitment Status
Completed
Study Start Date
March 2016 (Actual)
Primary Completion Date
August 2017 (Actual)
Study Completion Date
August 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hill-Rom

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To determine if a therapy regimen including treatment with The MetaNeb® System has a positive impact on the rate of pulmonary complications that occur in high risk post-operative patients. This is a non-randomized facility (or hospital) level pre-post intervention study.
Detailed Description
Post-operative pulmonary complications (PPC) are associated with significant excess morbidity, mortality and healthcare expenditure. Although PPCs are an incompletely understood multifactorial syndrome, atelectasis is recognized as a critical component. A variety of strategies have been shown to reduce the risk for development of post-operative atelectasis including lung expansion (LE) therapies. Well-designed studies are needed to distinguish which LE approach has the greatest potential to optimize patient care, clinical outcomes and cost savings. Intrapulmonary percussive ventilation (IPV) devices have been in use for more than 25 years and are used widely in the acute care, post-surgical, and homecare setting. Such devices provide both LE and airway clearance therapy (ACT) for patients with obstructive and/or restrictive lung diseases and conditions. The MetaNeb® System is an LE expansion modality that incorporates all the physiological effects of IPV while providing additional therapeutic advantages intended primarily to more effectively treat or prevent pulmonary atelectasis. The study will be conducted in two stages. In Stage I of the study, a retrospective review of medical records for post-surgical patients, who received STANDARD THERAPY as defined by current hospital and respiratory care department policies and procedures will be performed. In Stage II, a CHANGE IN PRACTICE will be made and patients will receive standard care with the addition of therapy with The MetaNeb® System. Demographic, clinical & outcome data will be collected for eligible patients during the two stages of the study. Study staff will collect data from the medical records, following a protocol determined schedule.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atelectasis, Pulmonary Complications

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
419 (Actual)

8. Arms, Groups, and Interventions

Arm Title
METANEB
Arm Type
Experimental
Arm Description
Patients will receive standard care with the addition of therapy with The MetaNeb® System.
Intervention Type
Device
Intervention Name(s)
MetaNeb® System
Intervention Description
The treatment protocol used for Respiratory Care during the CHANGE IN PRACTICE period of the Study will be that prescribed by the patient's health care team in the routine standard care of each patient. With the exception of standard airway clearance and lung expansion procedures, other components of the patients respiratory care regimen will remain the same as during the standard therapy period, however the CHANGE IN PRACTICE will incorporate the use/treatment with The MetaNeb® System as an alternative to usual airway clearance and lung expansion procedures. Use of The MetaNeb® System will follow the labeling of the device.
Primary Outcome Measure Information:
Title
Significant Postoperative Pulmonary Complication Incidence
Description
Patient Requires Prolonged Mechanical Ventilation, Patient requires prolonged respiratory support for > 24 hours post-surgery, Diagnosis of Pneumonia Within Seven (7) Days, Readmission to ICU (or transfer to an elevated level of care) for pulmonary complications within seven (7) days of discharge
Time Frame
Occurs within seven (7) days of the post-surgical admission will be considered a Significant Postoperative Pulmonary Complication
Secondary Outcome Measure Information:
Title
Requirement for invasive mechanical ventilation for > 48 hours within seven (7) days of the post-surgical hospital admission
Time Frame
from the time of the post-surgical admission to the hospital unit until discharge from the hospital, up to 8 weeks
Title
Requirement for respiratory support > 48 hours within seven (7) days of the post-surgical hospital admission
Time Frame
from the time of the post-surgical admission to the hospital unit until time of discharge from the hospital, up to 8 weeks
Title
Length of ICU stay during initial hospital stay
Time Frame
Total days/hours until time of discharge from the hospital, up to 8 weeks
Title
Length of hospital stay during initial hospital stay
Time Frame
Time of admission until time of discharge from the hospital, up to 8 weeks
Title
Readmission to ICU and transfers to elevated level of care for pulmonary complications during initial hospital stay
Time Frame
during hospital stay, up to 8 weeks
Title
Readmission to hospital
Time Frame
30 days following discharge from the hospital
Title
Time on Mechanical Ventilation
Time Frame
total hours/days from the time of the post-surgical admission to the hospital unit until time of discharge from the hospital, up to 8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years Post-thoracic, -upper abdominal or -aortic surgery Open surgical procedure Incision at or above the umbilicus High risk defined by: Documented ASA class ≥ 3 OR Documented ASA class 2 AND One or more of the following: Current smoker or smoking history within past 6 months History of COPD Documented obesity and/or BMI ≥ 30 kg/m2 Age ≥ 75 Exclusion Criteria: Contraindication to Continuous High Frequency Oscillation (CHFO) therapy Minimally invasive, or ". . . scopic" procedure. Spinal surgery involving a posterior approach Surgery for organ transplant Chronic invasive positive pressure ventilation (PPV)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Timothy Liesching, MD, FCCP
Organizational Affiliation
Lahey Hospital & Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Maurizio Cereda, MD
Organizational Affiliation
University of Pennsylvania
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Toan Huynh, MD FACS FCCM
Organizational Affiliation
Carolinas Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lahey Hospital and Medical Center
City
Burlington
State/Province
Massachusetts
ZIP/Postal Code
01805
Country
United States
Facility Name
Carolinas Medical Center
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28203
Country
United States
Facility Name
Hospital of the University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
31362061
Citation
Huynh TT, Liesching TN, Cereda M, Lei Y, Frazer MJ, Nahouraii MR, Diette GB. Efficacy of Oscillation and Lung Expansion in Reducing Postoperative Pulmonary Complication. J Am Coll Surg. 2019 Nov;229(5):458-466.e1. doi: 10.1016/j.jamcollsurg.2019.06.004. Epub 2019 Jul 27.
Results Reference
derived

Learn more about this trial

Evaluation of The MetaNeb® System to Reduce Postoperative Pulmonary Complications

We'll reach out to this number within 24 hrs